
Citation: Jia-hui SONG, Wen-bing LIU, Guang-wen CAO . Epidemiological characteristics and preventive measures for dengue fever[J]. Shanghai Journal of Preventive Medicine, 2017, 29(1): 17-22. doi: 10.19428/j.cnki.sjpm.2017.01.005

登革热的流行病学特征和预防措施
English
-
-
[1]
BRADY O J, GETHING P W, BHATT S.Refining the global spatial limits of dengue virus transmission by evidence-based consensus[J]. PLoS Negl Trop Dis, 2012, 6, (8): e1760-. doi: 10.1371/journal.pntd.0001760
-
[2]
熊益权, 陈青.1978—2014年我国登革热的流行病学分析[J]. 南方医科大学学报, 2014, 34(32): 1822-1825.
-
[3]
杜建伟, 潘先海.中国登革热流行概况与流行特征[J]. 中华流行病学杂志, 2010, 31(12): 1429-1433. doi: 10.3760/cma.j.issn.0254-6450.2010.12.025
- [4]
-
[5]
张顺先, 王英, 闫磊.我国2005—2012年登革热流行病学特征分析[J]. 中国医药指南, 2013, (16): 401-402. doi: 10.3969/j.issn.1671-8194.2013.16.309
-
[6]
BHATT S, GETHING P W, BRADY O J.The global distribution and burden of dengue[J]. Nature, 2013, 496, (7446): 504-507. doi: 10.1038/nature12060
-
[7]
李凌华, 张复春, 唐小平.登革热的防治与挑战[J]. 中华传染病杂志, 2014, 32(12): 760-762. doi: 10.3760/cma.j.issn.1000-6680.2014.12.015
-
[8]
QIU F X, GUBLER D J, LIU J C.Dengue in China:a clinical review[J]. Bull World Health Organ, 1993, 71, (3-4): 249-359.
-
[9]
LI F S, YANG F R, SONG J C.Etiologic and serologic investigations of the 1980 epidemic of dengue fever on Hainan Island, China[J]. Am J Trop Med Hyg, 1986, 35, (5): 1051-1054. doi: 10.4269/ajtmh.1986.35.1051
-
[10]
QIU F X, CHEN Q Q, HO Q Y.The first epidemic of dengue hemorrhagic fever in the People's Republic of China[J]. Am J Trop Med Hyg, 1991, 44, (3): 364-370.
-
[11]
XU G Z, DONG H J, SHI N F.An outbreak of dengue virus serotype 1 infectionin Cixi, NingBo, People's Republic of China, 2004, associated a traveler from Thailand and high density of aedes albopictus[J]. Am J Trop Med Hyg, 2007, 76, (6): 1182-1188.
-
[12]
LIU C, LIU Q, LIN H.Spatial analysis of dengue fever in Guangdong Province, China, 2001-2006[J]. Asia Pac J Public Health, 2014, 26, (1): 58-66. doi: 10.1177/1010539512472356
-
[13]
樊景春, 刘起勇.气候变化对登革热传播媒介影响研究进展[J]. 中华流行病学杂志, 2013, 34(7): 745-749.
-
[14]
GUZMAN M G, HALSTEAD S B, ARTSOB H.Dengue: a continuing global threat[J]. Nat Rev Microbiol, 2010, 8: S7-S16. doi: 10.1038/nrmicro2460
-
[15]
PERERA R, KHALIQ M, KUHN R J.Closing the door on flaviviruses:entry as a target for antiviral drug design[J]. Antiviral Res, 2008, 80, (1): 11-22. doi: 10.1016/j.antiviral.2008.05.004
-
[16]
CALISHER C H, KARABATSOS N, DALRYMPLE J M.Antigenic relationships between flaviviruses as determinde by cross-neutralization tests with polyclonal antisera[J]. J Gen Virol, 1989, 70, (1): 37-43. doi: 10.1099/0022-1317-70-1-37
-
[17]
FRIDE J R, GIBBONS R V, KALAYANAROO J S.Serotype specific differences in the risk of dengue hemorrhagic fever:an analysis of data collected in Bangkok, Thailand from 1994 to 2004[J]. PloS Negl Trop Dis, 2010, 4, (3): e617-. doi: 10.1371/journal.pntd.0000617
-
[18]
俞守义.现代热病学[M].北京:北京军事医学科学出版社, 2012:360-366.
-
[19]
WORLD HEALTH ORGANIZATION.Dengue: Guidelines for diagnosis, treatment, prevention and control[M]. Geneva: World Health Organization, 2009:25-54.
-
[20]
赵彩彦.感染性疾病首诊手册[M].北京:人民军医出版社, 2010:280-290.
-
[21]
WORLD HEALTH ORGANIZATION.Global strategy for dengue prevention and control 2012-2020[M].Geneva: World Health Organization, 2012.
-
[22]
李淑华, 方美玉, 刘世建.应用单管巢式多重PCR技术检测登革病毒及分型[J]. 第二军医大学学报, 2010, 31(2): 152-155.
-
[23]
叶子, 黄应雄, 蒋鹏.2014年广州地区158例登革热住院患者临床特征分析[J]. 中华危重急救医学, 2015, 27(4): 300-304.
-
[24]
FLIPSE J, WILSCHUT J, SMIT J M.Molecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans[J]. Traffic, 2013, 14, (1): 25-35. doi: 10.1111/tra.2013.14.issue-1
-
[25]
NAM V S, YEN N T, HOLYNSKA M.National progress in dengue vector control in Vietnam: survey for mesocyclops (copepoda), micronecta (corixidae), and fish as biological control agents[J]. Am J Trop Med Hyg, 2000, 62, (1): 5-10. doi: 10.4269/ajtmh.2000.62.5
-
[26]
AASKOV J G, BEKTAS A, DIEP V T B.Control of Aedes vectors of dengue in three provinces of Vietnam by use of mesocyclops (copepoda) and community-based methods validated by entomologic, clinical, and serological surveillance[J]. Am J Trop Med Hyg, 2002, 66, (1): 40-48. doi: 10.4269/ajtmh.2002.66.40
-
[27]
WRIGHT P F, DURBIN A P, WHITEHEAD S S.Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4Δ30-4995 in healthy adult volunteers[J]. Am J Trop Med Hyg, 2009, 81, (5): 834-841. doi: 10.4269/ajtmh.2009.09-0131
-
[28]
MORRISON D, LEGG T T, BILLING C W.A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults[J]. J Infect Dis, 2010, 201, (3): 370-377. doi: 10.1086/649521
-
[29]
FERGUSON N M, RODRÍGUEZ-BARRAQUER I, DORIGATTI I.Benefits and risks of the Sanofi-Pasteur dengue vaccine: modeling optimal deployment[J]. Science, 2016, 353, (6303): 1033-1036. doi: 10.1126/science.aaf9590
-
[30]
GALULA J U, SHEN W F, CHUANG S T.Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine[J]. J Virol, 2014, 88, (18): 10813-10830. doi: 10.1128/JVI.00810-14
-
[1]

计量
- PDF下载量: 11
- 文章访问数: 9704
- 引证文献数: 0